Copeptin: When to Order This Test

What Is Copeptin and Why Is It Measured Instead of Vasopressin?

Copeptin is the 39-amino-acid C-terminal glycopeptide cleaved from preprovasopressin during vasopressin synthesis. Because it is released in a 1:1 molar ratio with arginine vasopressin (AVP) and is far more stable in plasma, copeptin serves as an accurate, practical surrogate for AVP measurement.

Direct AVP assays have been available for decades, yet their clinical use has been limited by AVP's short half-life of roughly 5 to 15 minutes, its tendency to bind platelets during sample processing, and the need for rapid cold-centrifugation protocols that most routine labs cannot guarantee. Copeptin, by contrast, remains stable at room temperature for at least 7 days in EDTA plasma, making it suitable for batched analysis in standard reference laboratories.

Molecular Origin and Secretion

Preprovasopressin is synthesized in hypothalamic magnocellular neurons. During axonal transport to the posterior pituitary, enzymatic cleavage generates three fragments: AVP itself, neurophysin II, and copeptin. All three are released into circulation together in response to osmotic stimuli and hypovolemia. Copeptin concentrations therefore rise and fall in parallel with AVP under every physiologic condition studied so far, including hypertonic saline infusion, physical stress, and hypoglycemia [1].

Why Stability Matters

A 2011 study in the Journal of Clinical Endocrinology and Metabolism (N=50 healthy volunteers) confirmed that copeptin measured in samples stored at 22°C for 7 days showed less than 10 percent degradation, whereas AVP in the same samples degraded by more than 60 percent within 24 hours [2]. This stability difference is the core practical reason copeptin has replaced direct AVP measurement in most endocrine centers.

Primary Clinical Indication: Differentiating Polyuria-Polydipsia Syndrome

The single most common reason to order copeptin is to distinguish among the three disorders that produce hypotonic polyuria (urine output >50 mL/kg/day with urine osmolality <300 mOsm/kg): central diabetes insipidus (CDI), nephrogenic diabetes insipidus (NDI), and primary polydipsia (PP).

Before copeptin testing became widely available, the water deprivation test followed by desmopressin administration was the standard approach. That test carries a risk of severe dehydration, requires 8 to 18 hours of supervised fluid restriction, and produces inconclusive results in approximately 30 to 40 percent of patients who have partial CDI or PP [3].

The Hypertonic Saline Stimulation Protocol

The Endocrine Society's 2023 Clinical Practice Guideline on the Diagnosis and Management of Diabetes Insipidus recommends hypertonic saline infusion combined with copeptin measurement as the preferred first-line diagnostic approach in patients who can tolerate the procedure [4]. The protocol is:

1. Establish IV access and obtain a baseline plasma sodium and copeptin.
2. Infuse 3 percent sodium chloride at 0.10 mL/kg/min.
3. Measure plasma sodium every 30 minutes.
4. Once plasma sodium reaches 150 mmol/L (or symptoms develop), draw a final copeptin.
5. Interpret: copeptin above 4.9 pmol/L rules out CDI; copeptin at or below 4.9 pmol/L confirms CDI.

A landmark 2018 prospective study published in The New England Journal of Medicine (N=156 patients with confirmed polyuria-polydipsia) showed that the hypertonic saline-stimulated copeptin cutoff of 4.9 pmol/L diagnosed CDI with 96 percent accuracy, outperforming the water deprivation test at 76 percent accuracy [3].

Distinguishing Central from Nephrogenic DI

Once CDI is confirmed by a low stimulated copeptin, the next question is whether the lesion is in the hypothalamus or pituitary (central) versus the kidney's failure to respond to AVP (nephrogenic). Patients with NDI have intact hypothalamic AVP/copeptin secretion, so their copeptin rises normally or above normal during osmotic stress. A basal copeptin value above 21.4 pmol/L in a polyuric patient strongly suggests NDI, because the kidneys are not responding and the hypothalamus is compensating with excess AVP output [5].

Arginine Stimulation as an Alternative

For patients in whom hypertonic saline is contraindicated (uncontrolled hypertension, heart failure, severe renal disease), intravenous arginine infusion provides an alternative osmolality-independent stimulus for copeptin release. A 2019 study in JAMA (N=158) found that copeptin 60 minutes after arginine 0.5 g/kg IV above a cutoff of 3.8 pmol/L distinguished CDI from PP with 93.4 percent sensitivity and 92.4 percent specificity [6]. The Endocrine Society guideline lists arginine stimulation as an acceptable alternative when hypertonic saline cannot be used.

When to Order Copeptin: Specific Clinical Triggers

Unexplained Polyuria With Low Urine Osmolality

Any patient producing more than 3 liters of urine per day with a urine osmolality consistently below 300 mOsm/kg should have copeptin measured. Solute diuresis from uncontrolled diabetes mellitus, high protein intake, or diuretic use must be excluded first by measuring urine sodium, potassium, urea, and glucose. Once solute diuresis is ruled out, the polyuria-polydipsia differential narrows to CDI, NDI, and PP, all of which require copeptin for accurate sub-classification.

Post-Surgical Pituitary Monitoring

Patients who have undergone transsphenoidal resection of a pituitary adenoma are at risk for delayed CDI, which may appear 3 to 5 days postoperatively as posterior pituitary edema resolves. Daily copeptin measurement in the first week after surgery can detect this before the patient becomes clinically symptomatic. A copeptin value falling below 2.5 pmol/L in the post-operative period predicts CDI onset within 24 hours with approximately 85 percent sensitivity [7].

Hyponatremia Work-Up

Copeptin is increasingly used in the hyponatremia evaluation to confirm or exclude SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion). In SIADH, AVP secretion is tonically elevated despite low plasma osmolality. A high copeptin (above approximately 3.0 pmol/L) in the setting of hypo-osmotic hyponatremia, normal volume status, and high urine sodium supports SIADH. The European Clinical Practice Guideline on hyponatremia from 2014 notes that directly measuring AVP or its surrogate assists in confirming non-osmotic AVP release [8].

Traumatic Brain Injury

AVP dysregulation is common after TBI. Both transient CDI (from posterior pituitary contusion) and SIADH can develop within the first 72 hours. Copeptin measured on admission and at 48 hours helps triage which patients need desmopressin replacement versus fluid restriction. A 2021 observational study (N=312 TBI patients) found that copeptin below 2.2 pmol/L within 12 hours of admission predicted clinically significant CDI requiring desmopressin in 88 percent of cases [9].

Adrenal Insufficiency and Pituitary Disease

Copeptin is also low in patients with co-existing hypothalamic-pituitary-adrenal dysfunction, because cortisol deficiency itself reduces AVP secretion at certain osmotic thresholds. Clinicians evaluating panhypopituitarism should include copeptin to assess posterior pituitary reserve alongside anterior pituitary hormone panels.

Normal Copeptin Range

The reference interval for copeptin varies modestly by laboratory platform and the assay generation used. Based on published normative data from the KORA cohort (N=4,658 adults) and the manufacturer-validated range for the BRAHMS Copeptin US KRYPTOR assay, the following framework applies:

| Clinical State | Copeptin Range (pmol/L) | Interpretation | |---|---|---| | Fasting basal (healthy adult) | 1.0 to 13.8 | Normal posterior pituitary reserve | | Post-hypertonic saline (>150 mmol/L Na) | >4.9 | Rules out CDI | | Post-arginine (0.5 g/kg IV, 60 min) | >3.8 | Rules out CDI | | Suspected NDI (basal, polyuric) | >21.4 | Consistent with NDI | | SIADH (hypo-osmotic hyponatremia) | >3.0 | Supports non-osmotic AVP release | | Post-pituitary surgery (predicts CDI) | <2.5 | Monitor closely; desmopressin may be needed |

Sex-based differences exist: basal copeptin is approximately 25 percent higher in men than women (median 5.1 vs. 3.5 pmol/L in the KORA cohort), and most clinical cutoffs have been validated in mixed-sex cohorts [10]. Some expert panels recommend sex-specific cutoffs, although the Endocrine Society 2023 guideline currently uses a single cutoff of 4.9 pmol/L for the stimulated test regardless of sex.

Age and Physiologic Variation

Copeptin rises with age and with increasing body mass index. In adults over 65, basal values may reach 15 to 20 pmol/L even in the absence of disease, reflecting reduced renal concentrating capacity and mild chronic hyperosmolality. Clinicians should request age-matched reference intervals from their reference laboratory and not apply pediatric cutoffs to elderly patients.

What Does a High Copeptin Mean?

A copeptin value elevated above the reference range in a symptomatic patient points toward one of several mechanisms.

Nephrogenic Diabetes Insipidus

The most striking copeptin elevations (often 10 to 50 times the upper limit of normal) occur in NDI. The kidneys fail to concentrate urine despite adequate AVP, so the hypothalamus compensates with massive oversecretion. NDI may be genetic (aquaporin-2 or V2-receptor mutations), drug-induced (lithium use in bipolar disorder is the most common cause in adults), or structural (chronic kidney disease, hypercalcemia, hypokalemia) [5].

SIADH and Non-Osmotic Stimuli

In SIADH, copeptin is elevated relative to plasma osmolality, the hallmark being that AVP secretion continues despite low tonicity. Nausea, pain, surgery, and most medications that cause SIADH act through non-osmotic pathways that copeptin will reflect.

Acute Illness and Stress

Copeptin rises sharply with physiologic stress: myocardial infarction, sepsis, pneumonia, and major surgery all drive copeptin above 10 pmol/L within hours. Several studies have evaluated copeptin as a prognostic marker in acute coronary syndrome; the OPTIMIST trial found that copeptin above 14 pmol/L on admission predicted 30-day mortality independently of troponin [11]. This stress-response phenomenon means that a high copeptin in an acutely ill patient does not necessarily indicate primary AVP axis disease.

What Does a Low Copeptin Mean?

A low basal or stimulated copeptin confirms inadequate posterior pituitary AVP secretion.

Central Diabetes Insipidus

CDI results from destruction or dysfunction of AVP-producing neurons in the hypothalamus or from failure of transport to the posterior pituitary. Causes include craniopharyngioma, Langerhans cell histiocytosis, germinoma, head trauma, autoimmune hypophysitis, and post-surgical damage. A stimulated copeptin at or below 4.9 pmol/L in the hypertonic saline protocol confirms CDI with 96 percent accuracy [3].

Gestational DI

Pregnancy can unmask subclinical CDI or produce a transient gestational form because placental vasopressinase degrades AVP. Copeptin is also degraded by vasopressinase, so gestational DI may present with low-normal basal copeptin and an inadequate stimulated response. Clinicians managing polyuria in pregnancy should order copeptin alongside placental alkaline phosphatase and vasopressinase activity if available.

Over-Hydration and Primary Polydipsia

In PP, excessive water intake chronically suppresses AVP. Basal copeptin is typically low-normal (below 2.5 pmol/L), and unlike CDI, it rises appropriately to above 4.9 pmol/L with osmotic stimulation. This stimulated rise is the key discriminator between PP and CDI.

Can You Raise or Lower Copeptin?

Copeptin reflects the body's AVP axis response to osmolality and volume status. It is not a target for direct pharmacologic manipulation in the same way that, say, TSH is suppressed with levothyroxine. Clinically, however, specific interventions do shift copeptin levels.

Interventions That Raise Copeptin

• Hypertonic saline infusion (0.10 mL/kg/min of 3% NaCl): the standard diagnostic stimulus; raises copeptin within 90 minutes.
• Arginine infusion (0.5 g/kg IV over 30 minutes): raises copeptin through osmolality-independent mechanisms; useful when saline is contraindicated.
• Glucocorticoid withdrawal: stopping long-term glucocorticoid therapy transiently raises AVP and copeptin as the HPA axis reactivates.
• Nausea and emesis: some of the strongest non-osmotic stimuli for AVP release; copeptin can double within 30 minutes of emesis.

Interventions That Lower Copeptin

• Desmopressin (DDAVP) does not lower copeptin directly, but its V2-receptor agonism normalizes the osmotic feedback loop, which over days reduces compensatory AVP secretion in partial CDI.
• Treating the underlying cause of SIADH (stopping an offending drug, treating pneumonia, resecting a small-cell lung carcinoma) will normalize copeptin as the non-osmotic stimulus resolves.
• Fluid loading: acute volume expansion suppresses AVP through baroreflex pathways. This is the physiologic basis of low copeptin in PP patients who drink compulsively.

There is no dietary supplement or lifestyle intervention with validated evidence for clinically meaningful copeptin reduction in healthy adults. Patients sometimes ask about reducing fluid intake to "test" copeptin levels at home. This is not recommended outside a supervised clinical protocol because rapid dehydration in undiagnosed CDI carries a risk of hypernatremic crisis.

Ordering Copeptin: Practical Logistics

Specimen and Processing Requirements

Copeptin should be collected in a pre-chilled EDTA tube (lavender top), placed immediately on ice, and centrifuged within 4 hours at 4°C. If same-day processing is not possible, plasma should be separated and frozen at minus 20°C. Serum (red or gold top) is acceptable on platforms validated for serum use, including the BRAHMS KRYPTOR US and the Luminex MAGPIX-based assays.

Hemolyzed samples falsely raise copeptin. Request a new draw if the sample arrives hemolyzed.

Fasting and Timing Considerations

For a basal copeptin draw, an 8-hour overnight fast is standard. Physical exercise, nausea, and any painful procedure should be avoided for at least 2 hours before collection, as these stimuli raise copeptin non-specifically. For stimulated tests, the patient must have IV access placed well before infusion, and plasma sodium should be confirmed below 147 mmol/L before starting hypertonic saline.

Interpretation in the Context of Plasma Sodium

Copeptin cannot be interpreted in isolation. Every copeptin result must be paired with a simultaneous plasma sodium and osmolality. The relationship between plasma sodium (or osmolality) and copeptin defines where on the osmoregulatory response curve the patient sits. A copeptin of 5 pmol/L is reassuring if plasma sodium is 145 mmol/L (strong osmotic stimulus), but the same value is inappropriately elevated if plasma sodium is 128 mmol/L (SIADH pattern).

Copeptin Versus the Water Deprivation Test: A Direct Comparison

The traditional water deprivation test followed by desmopressin has been the reference standard for diagnosing DI for 50 years, but it has significant limitations. The 2018 NEJM study by Fenske et al. (N=156) put both tests head-to-head [3]:

• Water deprivation test accuracy: 76 percent.
• Hypertonic saline-stimulated copeptin accuracy: 96 percent.
• Copeptin misclassification rate for partial CDI: 4 percent versus 37 percent for water deprivation.

The Endocrine Society guideline states directly: "We recommend using hypertonic saline-stimulated copeptin measurement rather than indirect water deprivation testing when expertise and the assay are available" [4].

The water deprivation test remains useful in settings where copeptin assays are not available or where saline infusion is contraindicated, but in any center that can run copeptin, the stimulated copeptin test should be the first-line approach.

Special Populations

Pediatric Patients

Normative copeptin data in children younger than 12 are limited. A 2020 multicenter study (N=137 children aged 1 to 17) found that the 4.9 pmol/L cutoff performed comparably in adolescents above 14 but that children below 10 had a higher false-positive rate for CDI with the stimulated protocol [12]. Pediatric endocrinologists should use age-matched reference intervals and consider a lower stimulation dose of hypertonic saline (0.05 mL/kg/min) in children below 30 kg.

Pregnant Women

As described in the gestational DI section above, vasopressinase activity rises from the first trimester and peaks at term. Copeptin thresholds validated in non-pregnant adults may not apply directly. Consult a maternal-fetal medicine specialist or endocrinologist before using copeptin to rule in or out CDI during pregnancy.

Patients on Lithium

Lithium-induced NDI affects 20 to 40 percent of patients on long-term lithium therapy. These patients will show elevated basal copeptin (often above 15 pmol/L) with a paradoxically dilute urine. Ordering copeptin in this population serves primarily to confirm that the hypothalamus is functioning (high copeptin) and the defect is renal (no urinary concentration despite high AVP).